How big is Progyny, Inc.?

As of Jun 18, Progyny, Inc. has a market capitalization of $1.85 billion, with net sales of $1.21 billion and a net profit of $52.49 million for the latest four quarters. The balance sheet as of December 2024 shows shareholder's funds of $422.06 million and total assets of $612.15 million.

As of Jun 18, Progyny, Inc. has a market capitalization of 1,845.51 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,213.18 million and a net profit of 52.49 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the balance sheet shows shareholder's funds of 422.06 million and total assets of 612.15 million.

What does Progyny, Inc. do?

Progyny, Inc. is a fertility benefits management company in the U.S. that provides fertility and family building solutions, with a recent net sales of $324 million and a market cap of approximately $1.85 billion.

Overview:<BR>Progyny, Inc. is a fertility benefits management company specializing in fertility and family building benefits solutions in the United States, operating in the Miscellaneous industry and categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 324 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 15 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,845.51 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.54 <BR>Return on Equity: 11.24% <BR>Price to Book: 3.95<BR><BR>Contact Details:<BR>Address: 1359 BROADWAY, 2ND FLOOR, NEW YORK NY: 10018 <BR>Tel: 1 212 8883124 <BR>Fax: 1 302 6745266 <BR>Website: https://www.progyny.com/

Should I buy, sell or hold Progyny, Inc.?

Who are in the management team of Progyny, Inc.?

As of March 2022, Progyny, Inc.'s management team includes Dr. Beth Seidenberg (Independent Chairman), Mr. David Schlanger (CEO), and Directors Malissia Clinton, Roger Holstein, Frederick Cohen, Kevin Gordon, and Jeffrey Park. They are responsible for guiding the company's strategy and operations.

As of March 2022, the management team of Progyny, Inc. includes the following individuals:<BR><BR>- Dr. Beth Seidenberg, who serves as the Independent Chairman of the Board of Directors.<BR>- Mr. David Schlanger, who is the Chief Executive Officer and a Director.<BR>- Ms. Malissia Clinton, who is a Director.<BR>- Mr. Roger Holstein, who is also a Director.<BR>- Dr. Frederick Cohen, serving as an Independent Director.<BR>- Mr. Kevin Gordon, who is an Independent Director.<BR>- Mr. Jeffrey Park, who is another Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategy and operations.

Is Progyny, Inc. technically bullish or bearish?

As of October 3, 2025, Progyny, Inc. shows a mildly bearish trend, with bearish signals from the weekly MACD and Bollinger Bands, despite a mildly bullish daily moving average, and has underperformed the S&P 500 recently.

As of 3 October 2025, the technical trend for Progyny, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD is bearish, and Bollinger Bands are also indicating a bearish stance. Moving averages show a mildly bullish signal on the daily timeframe, but the overall trend is tempered by the weekly KST and Dow Theory, both indicating a mildly bearish condition. The stock has underperformed against the S&P 500 over the past week and month, with returns of -5.74% and -10.47% compared to the S&P 500's gains of 1.09% and 4.15%, respectively. Overall, the current technical stance is mildly bearish.

Is Progyny, Inc. overvalued or undervalued?

As of November 7, 2025, Progyny, Inc. is considered overvalued with a P/E ratio of 35 and a Price to Book Value of 3.98, despite a recent 1-year return of 42.20%, as it has underperformed over the past 3 and 5 years with returns of -37.28% and -18.58%, respectively.

As of 7 November 2025, Progyny, Inc. has moved from a fair to an expensive valuation grade. The company appears to be overvalued, with a P/E ratio of 35, a Price to Book Value of 3.98, and an EV to EBITDA ratio of 20.94. In comparison to peers, Progyny's P/E ratio is significantly higher than ADT, Inc. at 10.02 and MAXIMUS, Inc. at 15.70, indicating that it is priced at a premium relative to its industry counterparts.<BR><BR>Despite a strong recent performance, with a 1-year return of 42.20% compared to the S&P 500's 12.65%, the long-term outlook shows a concerning trend, as the stock has underperformed over 3 and 5 years with returns of -37.28% and -18.58%, respectively. This suggests that while the company has had short-term gains, its long-term valuation may not be justified given its current metrics.